179 related articles for article (PubMed ID: 23357140)
1. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.
Taseva K; Fischer S; Passauer J; Weiss N; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):45-50. PubMed ID: 23357140
[TBL] [Abstract][Full Text] [Related]
2. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
3. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein apheresis--more than just cholesterol reduction?
Neumann CL; Schulz EG; Hagenah GC; Platzer U; Wieland E; Schettler V
Atheroscler Suppl; 2013 Jan; 14(1):29-32. PubMed ID: 23357137
[TBL] [Abstract][Full Text] [Related]
5. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
6. Current situation of lipoprotein apheresis in Saxony.
Julius U; Taseva K; Fischer S; Passauer J; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):51-5. PubMed ID: 23357141
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein apheresis: state of the art and novelties.
Stefanutti C; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):19-27. PubMed ID: 23357136
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
10. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
12. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M
Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
Berent T; Derfler K; Berent R; Sinzinger H
Atheroscler Suppl; 2019 Dec; 40():8-11. PubMed ID: 31818453
[TBL] [Abstract][Full Text] [Related]
15. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
16. Current standards in diagnosis and therapy of hyperlipoproteinemia.
Fischer S; Schatz U; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):15-8. PubMed ID: 23357135
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
19. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
[TBL] [Abstract][Full Text] [Related]
20. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
